Avista Pharma Solutions, Inc.

Merck Sharp + Dohme Corp.

Msd K.k.

Bharathi Pandi

Jason Daniel Speake

Joe B Perales

Weiming Fan

Brent Christopher Beck

Toshihiro Sakamoto

Tony Siu

Yoshio Ogino

Nobuhiko Kawanishi

Cyprian Okwara Ogbu

Michael Robert Peel

Joseph Alexander Moore, Iii

Michael James Malaska

Jennifer Freeman

Keqiang Li

Matthew G Jenks

Yu Onozaki

Hao Liu

Jeffrey A Adams

Shuliang Lee

Joseph A Moore, Iii

Thomas F N Haxell

Joseph A Iii Moore

The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.

Synthetic process and intermediates

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.

Chemical compounds

The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus Kinase inhibitors and are useful in the treatment or control of pruritus, associated with allergic dermatitis, atopic dermatitis in animals, and other disorders and indications where immunosuppression/immunomodulation would be desirable. Also described herein are methods of treating pruritus and atopic dermatitis by administering the compounds of the invention, which are JAK 1 inhibitors.

Sulfonamide derivatives as JAK inhibitors

The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

Inhibitors of Akt activity

Growing community of inventors

Cary, NC, United States of America

Bharathi Pandi